Characterization of breakthrough hemolysis events observed in the phase III randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria

Eculizumab is first-line treatment for paroxysmal nocturnal hemoglobinuria (PNH); however, approximately 11-27% of patients may experience breakthrough hemolysis (BTH) on approved doses of eculizumab. Ravulizumab, a new long-acting C5 inhibitor with a four times longer mean half-life than eculizumab...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Haematologica
Main Authors: Brodsky, Robert A., de Latour, Régis Peffault, Rottinghaus, Scott T., Röth, Alexander, Risitano, Antonio M., Weitz, Ilene C., Hillmen, Peter, Maciejewski, Jaroslaw P., Szer, Jeff, Lee, Jong Wook, Kulasekararaj, Austin G., Volles, Lori, Damokosh, Andrew I., Ortiz, Stephan, Shafner, Lori, Liu, Peng, Hill, Anita, Schrezenmeier, Hubert
Formato: Artigo
Idioma:Inglês
Publicado em: Fondazione Ferrata Storti 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7776354/
https://ncbi.nlm.nih.gov/pubmed/31949012
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2019.236877
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados